# A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors

> **NCT03695952** · — · ACTIVE_NOT_RECRUITING · sponsor: **Asan Medical Center** · enrollment: 100 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Biliary Tract Cancer

## Interventions

- **DRUG:** Nivolumab or pembrolizumab

## Key facts

- **NCT ID:** NCT03695952
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-07-01
- **Primary completion:** 2025-07-30
- **Final completion:** 2026-07-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03695952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03695952, "A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03695952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*